| Recruiting | Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemi NCT07073794 | Mayo Clinic | Phase 2 |
| Recruiting | Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation NCT05487846 | Thomas Jefferson University | N/A |
| Recruiting | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic C NCT06305598 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castrat NCT05805371 | City of Hope Medical Center | Phase 1 |
| Recruiting | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patie NCT05869682 | City of Hope Medical Center | Phase 2 |
| Recruiting | Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network NCT05627219 | Thomas Jefferson University | — |
| Recruiting | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Pr NCT05398302 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostat NCT06244004 | Northwestern University | Phase 2 |
| Recruiting | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIER NCT06040125 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Access to Genetic Testing in Underserved Patients With Cancer NCT06422455 | University of Southern California | N/A |
| Active Not Recruiting | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Pr NCT05241860 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer NCT05034562 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant NCT05547386 | Mayo Clinic | Phase 3 |
| Recruiting | Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients NCT05045066 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer NCT04716725 | Thomas Hope | Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Terminated | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Prog NCT04928820 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant NCT04489719 | University of Washington | — |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of NCT04592237 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemica NCT04585932 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET NCT04423211 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study NCT04447703 | Thomas Jefferson University | N/A |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Active Not Recruiting | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer NCT04267887 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Terminated | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Re NCT04279561 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT04159896 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With NCT04134208 | M.D. Anderson Cancer Center | Phase 4 |
| Active Not Recruiting | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer NCT03873805 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients NCT03987217 | University of Utah | EARLY_Phase 1 |
| Active Not Recruiting | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Pros NCT03517969 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT03805594 | University of California, San Francisco | Phase 1 |
| Completed | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bon NCT03707184 | University of Utah | Phase 2 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resis NCT03596710 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer NCT04050215 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer NCT03456804 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer NCT03448458 | Emory University | Phase 2 |
| Active Not Recruiting | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer NCT02881242 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Genetic Testing for Men With Metastatic Prostate Cancer NCT03503097 | University of Washington | — |
| Active Not Recruiting | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With NCT02893917 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer NCT03016741 | Northwestern University | Phase 4 |
| Unknown | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Can NCT02935205 | Mamta Parikh | Phase 1 / Phase 2 |
| Active Not Recruiting | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration- NCT03012321 | Northwestern University | Phase 2 |
| Completed | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate C NCT03123978 | Mamta Parikh | Phase 1 |
| Terminated | Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients NCT03011749 | Rigshospitalet, Denmark | N/A |
| Terminated | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies NCT02985021 | Seattle Institute for Biomedical and Clinical Research | Phase 2 |
| Active Not Recruiting | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT02807805 | Mamta Parikh | Phase 2 |
| Unknown | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer NCT02935023 | Shanghai Proton and Heavy Ion Center | Phase 2 |
| Terminated | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer NCT02516670 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients NCT02853097 | University of Southern California | — |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in NCT02703623 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients NCT02691975 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cance NCT02565901 | University of Washington | Phase 1 / Phase 2 |
| Completed | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin NCT02598895 | University of Washington | Phase 2 |
| Completed | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer NCT02532114 | University of Washington | Phase 1 |
| Completed | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prost NCT02555189 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Terminated | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant P NCT02491411 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Active Not Recruiting | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer NCT02522715 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Terminated | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistan NCT02429804 | Stanford University | Phase 1 |
| Completed | Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer NCT02458716 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cance NCT02159950 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or NCT02370355 | University of Southern California | — |
| Completed | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer NCT01881867 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy NCT01953640 | Mayo Clinic | — |
| Completed | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01503229 | University of Washington | Phase 2 |
| Completed | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Res NCT01505868 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary NCT00942331 | National Cancer Institute (NCI) | Phase 3 |